GlassScriptPhysician profile
Arunachalam Thenappan
NPI 1538189915
$24,275.21
in general payments reported to CMS, 2019-2025
74 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,043 · 2020: $1,966 · 2021: $2,161 · 2022: $2,839 · 2023: $11K · 2024: $3,062 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,493 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,225 · Travel and Lodging: $1,442 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,492.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,225.00 |
| Travel and Lodging | $1,441.96 |
| Education | $106.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,337.79 | 2019-2024 | |
| Janssen Biotech, INC. | $1,347.70 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $1,138.90 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $921.47 | 2019-2025 | Tagrisso, Lynparza |
| Genzyme Corporation | $804.99 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $765.18 | 2019-2024 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $654.30 | 2019-2024 | Opdivo, Krazati, Opdualag |
| Celgene Corporation | $642.77 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $587.28 | 2020-2024 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $579.90 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Daiichi Sankyo INC. | $537.84 | 2020-2025 | Enhertu, Injectafer |
| Lilly USA, LLC | $528.41 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $523.84 | 2019-2024 | |
| Seagen INC. | $442.56 | 2019-2023 | Tukysa, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $431.77 | 2019-2024 | Fruzaqla, Alunbrig, Vonvendi |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arunachalam Thenappan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.